Phase II Trial Currently Recruiting (Learn More)
Amplexd Therapeutics is developing investigational platform technologies for localized infectious disease and cancer interception — starting with HPV-associated cervical precancerous lesions, with a pipeline built to extend into other infectious disease, women's health, cancer prevention and dermatologic indications.
The Thesis
Infection is one of the most common and most treatable classes of human disease — and, left unresolved, one of its most consequential. Persistent infection doesn't just cause acute illness; certain pathogens can quietly drive tissue damage, chronic inflammation and, over years, precancerous change.
A meaningful share of cancers begin with an infection:
— associated with cancers of the liver, stomach, head and neck, genitalia, blood and other tissues.
We believe the next era of medicine treats the infection in its infancy, locally — with the goal of preventing cancers from forming and diseases from progressing.
The Approach
Antibiotics and antifungals are among the most significant medical inventions of the last century — but decades of use have driven rising antimicrobial resistance, and resistant infections are harder, slower and more expensive to treat with existing systemic drugs. At the same time, many common infections — genital, dermatologic, HPV-associated — are chronic, recurrent or persistent enough that a single systemic course often isn't the end of the story.
We think there's room for a different approach: therapies delivered locally, directly to the site of infection, designed to reduce reliance on systemic treatment and to reach disease that current standards of care manage imperfectly.
Cancer treatment has evolved the same way infectious disease treatment has — enormously effective once disease is advanced, at real cost to the body. We're building toward catching both kinds of disease earlier, while they're still localized, and treating them there.
Nature has produced biologically active molecules for billions of years. Modern pharmaceutical science lets us identify candidate molecules, isolate and characterize them, formulate them to pharmaceutical standards, and deliver them precisely where they're needed — our investigational programs pair botanical-origin active pharmaceutical ingredients with modern formulation science, localized drug delivery, and medical-device engineering, developed under pharmaceutical (not supplement or cosmetic) regulatory pathways.
The Technologies
An investigational, self-administered platform for high-risk HPV-driven precancer, with a franchise strategy designed to extend from cervical disease to other HPV-associated anatomic sites over time.
Investigational — not approved for any use.
An investigational drug-device photodynamic therapy platform pairing botanical-origin therapeutics with precision light activation. Its initial focus is HPV-associated precancer; the underlying platform is designed to extend to localized genital infections (including candida and bacterial infections) and dermatologic conditions.
Future indications reflect internal R&D planning, not current clinical programs.
An investigational localized delivery platform, not itself a single drug, designed to carry a range of therapeutic classes — antifungals, antimicrobials, live biotherapeutics, botanical and novel compounds — directly to vaginal and cervical tissue.
INVESTIGATIONAL DELIVERY PLATFORM (NOT A DRUG OR DEVICE IN ITS OWN RIGHT)
Leadership
Co-Founder & CEO
Patient-scientist, engineer, and award-winning founder, Alia Rahman co-founded Amplexd following her own experience with a precancerous condition. She leads the company's clinical development, fundraising, and commercialization of novel therapeutics and devices.
Co-Founder & Scientific Advisor
MIT-trained pharmacologist with 41 years of drug development experience, 2 FDA-approved drugs, 3 FDA-cleared devices, and 140+ U.S. patents. Supports Amplexd's product development and regulatory strategy.
We want to treat infection early enough — and locally enough — that fewer people ever reach late-stage disease, whether that's a resistant infection or a cancer.
